Jw Life Science Corp (234080) — Cash Flow-to-Debt Ratio
Jw Life Science Corp (234080) has a Cash Flow-to-Debt Ratio of 0.05x as of December 2025, meaning its operating cash flow of ₩5.08 Billion could theoretically repay 0% of its total liabilities (₩97.63 Billion) in one year. Explore Jw Life Science Corp long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Jw Life Science Corp Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Jw Life Science Corp across 11 annual periods. Also explore Jw Life Science Corp asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Jw Life Science Corp (2015–2025)
Year-by-year debt coverage analysis for Jw Life Science Corp. For market capitalisation and broader financial context, see Jw Life Science Corp market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.42x | ₩40.54 Billion | ₩97.63 Billion | ▲ +2.3% |
| 2024 | 0.41x | ₩50.69 Billion | ₩124.88 Billion | ▲ +4.2% |
| 2023 | 0.39x | ₩37.57 Billion | ₩96.44 Billion | ▲ +210.5% |
| 2022 | 0.13x | ₩14.13 Billion | ₩112.61 Billion | ▼ -63.4% |
| 2021 | 0.34x | ₩30.17 Billion | ₩87.97 Billion | ▼ -36.9% |
| 2020 | 0.54x | ₩46.75 Billion | ₩85.98 Billion | ▲ +76.5% |
| 2019 | 0.31x | ₩24.28 Billion | ₩78.79 Billion | ▼ -21.9% |
| 2018 | 0.39x | ₩36.13 Billion | ₩91.60 Billion | ▲ +72.5% |
| 2017 | 0.23x | ₩22.05 Billion | ₩96.43 Billion | ▲ +45.0% |
| 2016 | 0.16x | ₩16.08 Billion | ₩101.94 Billion | ▼ -40.9% |
| 2015 | 0.27x | ₩25.90 Billion | ₩97.05 Billion | — |